BioCryst Pharmaceuticals GAAP EPS of $1.12 beats by $1.07, revenue of $406.55M beats by $255.23M
Source: SeekingAlpha
2026-02-26 07:06:16 ET
More on BioCryst Pharmaceuticals
- BioCryst: The $700 Million Pivot From Oral Convenience To Injectable
- BioCryst: A Changed And Interesting Thesis For 2026
- 44th Annual J.P. Morgan Healthcare Conference
- BioCryst Pharmaceuticals Q4 2025 Earnings Preview
- BioCryst Pharmaceuticals reports prelim 2025 ORLADEYO revenue, provides 2026 guidance
Read the full article on Seeking Alpha
For further details see:
BioCryst Pharmaceuticals GAAP EPS of $1.12 beats by $1.07, revenue of $406.55M beats by $255.23M
BioCryst Pharmaceuticals Inc.
NASDAQ: BCRX
BCRX Trading
-1.71% G/L:
$8.325 Last:
1,409,572 Volume:
$8.40 Open:
BCRX Latest News
February 26, 2026 07:00:00 am
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
BCRX Stock Data
$1,391,931,498
199,991,369
0.01%
88
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
